🔗 Share this article World Health Organization Sounds Concern Over Severe Lack of Weight-Loss Injections Less than a tenth of patients that would benefit from obesity jabs such as Wegovy have access to them, states the global health agency as it publishes its initial guidance on the therapies. With more than one billion individuals worldwide now obese, it is calling for more widespread and fairer access to this class of drugs. Based on projections, more than two billion are projected to be obese by 2030 if no action is taken. "Our new guidelines recognises that obesity is a long-term condition that can be treated with thorough and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and logistical bottlenecks are significant barriers to broad availability to the injections that can aid individuals in losing significant body mass, explains the organization. Weight-Loss Drug Scarcity Even under the current most optimistic scenario, the supply of these medications could only cover approximately 100 million people – fewer than 10% of eligible patients, as stated by the WHO. The recommendation calls on nations and manufacturers to increase availability, through strategies such as voluntary licensing. Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026. How Weight-Loss Injections Operate These medications replicate a biological compound to slow digestion, suppress the appetite and boost the sense of being full so users eat less. People usually begin shedding pounds after several weeks of beginning the regular doses. Research suggests patients may put most of the weight back on a year later of stopping the treatment, as their normal food cravings come back. To be overweight or obese increases your likelihood for developing diseases, such as diabetes, heart disease, stroke, and some malignancies. Excess weight impacts individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.
Less than a tenth of patients that would benefit from obesity jabs such as Wegovy have access to them, states the global health agency as it publishes its initial guidance on the therapies. With more than one billion individuals worldwide now obese, it is calling for more widespread and fairer access to this class of drugs. Based on projections, more than two billion are projected to be obese by 2030 if no action is taken. "Our new guidelines recognises that obesity is a long-term condition that can be treated with thorough and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and logistical bottlenecks are significant barriers to broad availability to the injections that can aid individuals in losing significant body mass, explains the organization. Weight-Loss Drug Scarcity Even under the current most optimistic scenario, the supply of these medications could only cover approximately 100 million people – fewer than 10% of eligible patients, as stated by the WHO. The recommendation calls on nations and manufacturers to increase availability, through strategies such as voluntary licensing. Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026. How Weight-Loss Injections Operate These medications replicate a biological compound to slow digestion, suppress the appetite and boost the sense of being full so users eat less. People usually begin shedding pounds after several weeks of beginning the regular doses. Research suggests patients may put most of the weight back on a year later of stopping the treatment, as their normal food cravings come back. To be overweight or obese increases your likelihood for developing diseases, such as diabetes, heart disease, stroke, and some malignancies. Excess weight impacts individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.